



		EMLc	ATC codes: J01DI54
Indication	Carbapenem-resistant <i>Pseudomonas aeruginosa</i>	ICD11 code: MG50.80	
INN	Ceftolozane + tazobactam		
Medicine type	Chemical agent		
Antibiotic groups	R RESERVE		
List type	Complementary (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 1 g + 0.5 g powder for injection		
EML status history	Application rejected in 2019 (TRS 1021) Added in 2023 (TRS 1049)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org Read more about patents .		
Wikipedia	Ceftolozane + tazobactam		
DrugBank	Ceftolozane Tazobactam		

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the inclusion of ceftolozane + tazobactam as Reserve group antibiotic on the complementary list of the EML and EMLc for the treatment of infections caused or suspected to be caused by carbapenem-resistant *Pseudomonas aeruginosa*, a “Critical” priority pathogen on the 2017 WHO Priority Pathogens List. The Committee acknowledged that the clinical evidence for efficacy of ceftolozane + tazobactam against this specific pathogen is limited but considered that the availability of carbapenem-sparing alternatives for treatment of drug-resistant *Pseudomonas aeruginosa* was important as part of the strategy to limit/prevent further emergence and spread of carbapenem-resistant organisms.

